Marassi M, Fadini GP. The cardio-renal-metabolic connection: a review of the evidence. Cardiovasc Diabetol. 2023;22:195.
Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American heart association. Circulation. 2023;148:1606–35.
Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ. 2016;354:i4482.
Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro heart survey. Chest. 2010;138:1093–100.
Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263–72.
Wu J, Nadarajah R, Nakao YM, Nakao K, Wilkinson C, Cowan JC, et al. Temporal trends of cause-specific mortality after diagnosis of atrial fibrillation. Eur Heart J. 2023;44:4422–31.
Proietti M, Marzona I, Vannini T, Tettamanti M, Fortino I, Merlino L, et al. Long-term relationship between atrial fibrillation, multimorbidity and oral anticoagulant drug use. Mayo Clin Proc. 2019;94:2427–36.
Romiti GF, Proietti M, Bonini N, Ding WY, Boriani G, Huisman MV, et al. Clinical complexity domains, anticoagulation, and outcomes in patients with atrial fibrillation: a report from the GLORIA-AF registry phase II and III. Thromb Haemost. 2022;122:2030–41.
Romiti GF, Proietti M, Corica B, Bonini N, Boriani G, Huisman MV, et al. Implications of clinical risk phenotypes on the management and natural history of atrial fibrillation: a report from the GLORIA-AF. J Am Heart Assoc. 2023;12:e030565.
Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol. 2017;14:627–8.
Lip GYH, Kotalczyk A, Teutsch C, Diener H-C, Dubner SJ, Halperin JL, et al. Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF registry. Clin Res Cardiol. 2022;111:560–73.
Huisman MV, Teutsch C, Lu S, Diener H-C, Dubner SJ, Halperin JL, et al. Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from phase III of the GLORIA-AF registry. Clin Res Cardiol. 2022;111:548–59.
Huisman MV, Lip GYH, Diener HC, Dubner SJ, Halperin JL, Ma CS, et al. Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. Am Heart J. 2014;167:329–34.
Mazurek M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, et al. Safety and effectiveness of dabigatran at 2 years: final outcomes from phase II of the GLORIA-AF registry program. Am Heart J. 2019;218:123–7.
Noubiap JJ, Nansseu JR, Lontchi-Yimagou E, Nkeck JR, Nyaga UF, Ngouo AT, et al. Geographic distribution of metabolic syndrome and its components in the general adult population: a meta-analysis of global data from 28 million individuals. Diabetes Res Clin Pract. 2022;188:109924.
Essien UR, Kornej J, Johnson AE, Schulson LB, Benjamin EJ, Magnani JW. Social determinants of atrial fibrillation. Nat Rev Cardiol. 2021;18:763–73.
Romiti GF, Corica B, Mei DA, Vitolo M, Bucci T, Bisson A, et al. Association of comorbidity patterns with outcomes and relation with the ABC pathway effectiveness in European patients with atrial fibrillation. Heart Rhythm. 2025. Available from: https://www.heartrhythmjournal.com/action/showAbstract?pii=S1547527125002206
Mantovani M, Bucci T, Imberti JF, Lam SHM, Kotalczyk A, Boriani G, et al. Patterns of comorbidities, clinical course, and impact of the ABC Pathway for Integrated Care in patients with atrial fibrillation: a report from the prospective Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) Registry. Eur Heart J Qual Care Clin Outcomes [Internet]. 2025; Available from: https://doi.org/10.1093/ehjqcco/qcaf014
Liu Y, Lam SHM, Romiti GF, Huang B, Chen Y, Chao TF, et al. Renal function and adverse clinical events in anticoagulated patients with atrial fibrillation: insights from the GLORIA-AF registry phase III. J Thromb Thrombolysis. 2025;58:165–77.
Liu Y, Chen Y, Lam SHM, Huang B, Romiti GF, Alam U, et al. Diabetes mellitus and adverse clinical events in patients with atrial fibrillation: a report from the GLORIA-AF registry phase III. Diabetes Obes Metab. 2024;26:5795–804.
Wang A, Green JB, Halperin JL, Piccini JP Sr. Atrial fibrillation and diabetes mellitus: JACC review topic of the week. J Am Coll Cardiol. 2019;74:1107–15.
Zeitler EP, Johnson AE, Cooper LB, Steinberg BA, Houston BA. Atrial fibrillation and heart failure with reduced ejection fraction: new assessment of an old problem. JACC Heart Fail. 2024;12:1528–39.
Romiti GF, Corica B, Mei DA, Bisson A, Boriani G, Olshansky B, et al. Patterns of comorbidities in patients with atrial fibrillation and impact on management and long-term prognosis: an analysis from the prospective global GLORIA-AF registry. BMC Med. 2024;22:151.
Krittayaphong R, Treewaree S, Yindeengam A, Komoltri C, Lip GYH. Latent class analysis for the identification of phenotypes associated with increased risk in atrial fibrillation patients: The COOL-AF registry. Thromb Haemost [Internet]. 2025; Available from: https://doi.org/10.1055/a-2559-9994
Li J, Xu X, Yu Y, Sun Y, Cai L, Shen W, et al. Long-term weight change and transition of metabolic health status in middle life and the risk of atrial fibrillation. Heart Rhythm. 2025;22:e285–93.
Corica B, Romiti GF, Proietti M, Mei DA, Boriani G, Chao T-F, et al. Clinical outcomes in metabolically healthy and unhealthy obese and overweight patients with atrial fibrillation: findings from the GLORIA-AF registry. Mayo Clin Proc. 2024;99:927–39.
Harrington J, Carnicelli AP, Hua K, Wallentin L, Patel MR, Hohnloser SH, et al. Direct oral anticoagulants versus warfarin across the spectrum of kidney function: patient-level network meta-analyses from COMBINE AF. Circulation. 2023;147:1748–57.
Shimizu W, Yamashita T, Akao M, Atarashi H, Ikeda T, Koretsune Y, et al. Renal function and clinical outcomes among elderly patients with nonvalvular atrial fibrillation from ANAFIE. JACC Asia. 2023;3:475–87.
Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, et al. 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45:3314–414.
Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. 2023 ACC/AHA/ACCP/HRS guideline for the Diagnosis and Management of Atrial Fibrillation: A report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation. 2024;149:e1-156.
Wang Y, Guo Y, Qin M, Fan J, Tang M, Zhang X, et al. 2024 Chinese expert consensus guidelines on the diagnosis and treatment of atrial fibrillation in the elderly, endorsed by Geriatric Society of Chinese Medical Association (cardiovascular group) and Chinese Society of Geriatric Health Medicine (cardiovascular branch): Executive summary. Thromb Haemost. 2024;124:897–911.
Chao T-F, Joung B, Takahashi Y, Lim TW, Choi E-K, Chan Y-H, et al. 2021 focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation: Executive summary. Thromb Haemost. 2022;122:20–47.
Potpara T, Romiti GF, Sohns C. The 2024 European Society of Cardiology guidelines for diagnosis and management of atrial fibrillation: a viewpoint from a practicing clinician’s perspective. Thromb Haemost. 2024;124:1087–94.
Guo Y, Lane DA, Wang L, Zhang H, Wang H, Zhang W, et al. Mobile health technology to improve care for patients with atrial fibrillation. J Am Coll Cardiol. 2020;75:1523–34.
Chu M, Zhang S, Gong J, Yang S, Yang G, Sun X, et al. Telemedicine-based integrated management of atrial fibrillation in village clinics: a cluster randomized trial. Nat Med. 2025;31:1276–85.
Treewaree S, Lip GYH, Krittayaphong R. Non-vitamin K antagonist oral anticoagulant, warfarin, and ABC pathway adherence on hierarchical outcomes: win ratio analysis of the COOL-AF registry. Thromb Haemost. 2024;124:69–79.
Bucci T, Proietti M, Shantsila A, Romiti GF, Teo W-S, Park H-W, et al. Integrated care for atrial fibrillation using the ABC pathway in the prospective APHRS-AF registry. JACC Asia. 2023;3:580–91.
Romiti GF, Pastori D, Rivera-Caravaca JM, Ding WY, Gue YX, Menichelli D, et al. Adherence to the “atrial fibrillation Better Care” pathway in patients with atrial fibrillation: Impact on clinical outcomes-A systematic review and meta-analysis of 285,000 patients. Thromb Haemost. 2022;122:406–14.
Bucci T, Nabradalik K, Irlik K, Shantsila A, Romiti GF, Proietti M, et al. Adherence to the ABC (atrial fibrillation better care) pathway and risk of adverse outcomes in patients with chronic kidney disease: a report from the prospective APHRS-AF registry. Lancet Reg Health. 2025;58:101570.
Matsumoto S, Henderson AD, Jhund PS, Bauersachs J, Chioncel O, Claggett BL, et al. Finerenone and atrial fibrillation in heart failure: A secondary analysis of the FINEARTS-HF randomized clinical trial: A secondary analysis of the FINEARTS-HF randomized clinical trial. JAMA Cardiol. 2025;10:696–707.
Pabon MA, Filippatos G, Claggett BL, Miao MZ, Desai AS, Jhund PS, et al. Finerenone reduces new-onset atrial fibrillation across the spectrum of cardio-kidney-metabolic syndrome: The FINE-HEART pooled analysis. J Am Coll Cardiol. 2025;85:1649–60.